ACRS — Aclaris Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $506.50m
- $415.75m
- $7.83m
Annual cashflow statement for Aclaris Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -90.9 | -86.9 | -88.5 | -132 | -64.9 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 39.2 | 19.7 | 0.271 | 100 | 14.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.34 | -1.2 | 9.39 | 10.9 | 2.67 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -52.1 | -67.6 | -78.3 | -20.1 | -47.1 |
| Capital Expenditures | -0.308 | -0.605 | -1.31 | -35.9 | -0.944 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -167 | 13.2 | 47.5 | -33.8 | 49.3 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -168 | 12.6 | 46.2 | -69.8 | 48.4 |
| Financing Cash Flow Items | -3.12 | -0.034 | -0.102 | -0.409 | -5.86 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 225 | 72.9 | 26.7 | 74.5 | -5.86 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.29 | 17.9 | -5.4 | -15.3 | -4.61 |